Schertz Bergmann Rechtsanwälte: Alexander Zverev

7.6.2024 14:12:44 CEST | news aktuell GmbH | Press release

Share

As lawyers for Alexander Zverev, we declare on behalf of our client that the criminal proceedings under file number 250 Cs 184/23 have been dropped.

The criminal proceedings against Alexander Zverev were dropped and the case was terminated today by the court with the consent of the public prosecutor's office, Ms. Brenda Patea as joint plaintiff and Alexander Zverev's defence lawyer.  The penalty order is now groundless.

Alexander Zverev has agreed to this discontinuation via his defense lawyer, solely in order to shorten the proceedings - above all in the interests of their child. Alexander Zverev is considered innocent. The dismissal does not constitute a finding of guilt or an admission of guilt. The legal presumption of innocence remains unaffected.

Dr. Anna Sophie Heuchemer (Schertz Bergmann Attorneys at law)     

Katharina Dierlamm (Dierlamm Attorneys at law)                 

 

Pressekontakt

Schertz Bergmann Rechtsanwälte PartG mbB

Kurfürstendamm 53

10707 Berlin

Tel.: 030 88 00 150

E-Mail:cs@schertz-bergmann.de

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal licenses exclusive South Korean rights to Qutenza® to BCWorld Pharm5.3.2026 08:54:06 CET | Press release

Aachen, Germany & Yeoju, South Korea, 5 March 2026 – Grünenthal, a global leader in pain management and related diseases, and BCWorld Pharm Co., Ltd. ("BCWP"), a specialty company actively expanding and diversifying its pain management portfolio through global open innovation partnerships, announced today that they have entered into a definitive agreement whereby BCWP will have the exclusive South Korean rights to Qutenza®, a topical, non-systemic, non-opioid patch treatment. In Europe, the product is indicated for the management of peripheral neuropathic pain.

Grünenthal takes full ownership of Grünenthal Meds, the joint venture established with Kyowa Kirin for its established medicines brands2.3.2026 10:39:09 CET | Press release

Grünenthal acquired Kyowa Kirin International’s 49% stake in ‘Grünenthal Meds’, a joint venture formed in 2023 to market the established medicines portfolio from Kyowa Kirin International. Through this acquisition, Grünenthal assumes the sole responsibility of a portfolio comprising 12 brands across six therapeutic areas and >60 markets.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye